Prelude Therapeutics (PRLD) Current Assets (2019 - 2026)

Prelude Therapeutics (PRLD) has 8 years of Current Assets data on file, last reported at $84.6 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 17.39% year-over-year to $84.6 million; the trailing twelve-month figure through Mar 2026 stood at $84.6 million (down 17.39% YoY), and the FY2025 full-year result was $105.7 million, down 22.23% from the prior year.
• Current Assets retreated to $84.6 million in Q1 2026, from $105.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $270.0 million in Q1 2022 to a low of $58.3 million in Q3 2025.
• A 5-year average of $174.4 million and a median of $182.7 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets gained 17.18% in 2024 and slumped 62.7% in 2025, its largest moves.
• Tracing PRLD's Current Assets over 5 years: stood at $204.4 million in 2022, then climbed by 15.27% to $235.6 million in 2023, then tumbled by 42.32% to $135.9 million in 2024, then declined by 22.23% to $105.7 million in 2025, then dropped by 19.96% to $84.6 million in 2026.
• Business Quant data shows PRLD's Current Assets at $84.6 million in Q1 2026, $105.7 million in Q4 2025, and $58.3 million in Q3 2025.